Circadian Rhythms in Toxic Effects of the Serotonin Antagonist Ondansetron in Mice

References

• Bernstein B. J., Ong C. Efficacy of a single 8‐mg I.V. Dose of ondansetron hydrochloride for preventing chemotherapy‐induced emesis. Am. J. Health Syst. Pharm. 2002; 59: 650–652
   PubMedGoogle Scholar
• Boughattas N. A., Lévi F., Hecquet B., Lemaigre G., Roulon A., Fournier C., Reinberg A. Circadian time dependence of murine tolerance for carboplatin. Toxicol. Appl. Pharmacol. 1988; 96: 233–247
   PubMed Web of Science ®Google Scholar
• Boughattas N. A., Lévi F., Fournier C., Lemaigre G., Roulon A., Hecquet B., Mathé G., Reinberg A. Circadian rhythm in toxicities and tissue uptake of 1,2‐diammino‐cyclohexane(trans‐1)oxalatoplatinum(II) in mice. Cancer Res. 1989; 49: 3362–3368
   PubMed Web of Science ®Google Scholar
• Boughattas N. A., Ben Attia M., Ixart G., Lemaigre G., Mechkouri M., Reinberg A. Pharmacological blockage of serotonin biosynthesis and circadian changes in oxaliplatin toxicity in rats. Chronobiol. Int. 2002; 19: 1121–1136
   PubMed Web of Science ®Google Scholar
• Costall B., Domeney A. S.M., Naylor R. J., Tattersall F. D. 5‐Hydroxytryptamine M‐receptor antagonism to prevent cisplatin‐induced emesis. Neuropharmacology 1986; 25: 959–961
   PubMed Web of Science ®Google Scholar
• Costall B., Domeney A. M., Naylor R. J., Tyers M. B. Influence of GR38032F on the behavioural consequences of ceasing sub‐chronic treatment with drugs of abuse. Br. J. Pharmacol. 1988; 95: 905P
   Google Scholar
• Costall B., Jones B. J., Kelly M. E., Naylor R. J., Oakley N. R., Onaivi E. S., Tyers M. B. The effects of ondansetron (GR38032F) in rats and mice treated sub‐chronically with diazepam. Pharmacol. Biochem. Behav. 1989; 34: 769–778
   PubMedGoogle Scholar
• Costall B., Jones B. J., Kelly M. E., Naylor R. J., Onaivi E. S., Tyers M. B. Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse. Pharmacol. Biochem. Behav. 1990; 36: 339–344
   PubMed Web of Science ®Google Scholar
• De Prins J., Waldura J. Sightseeing around the single cosinor. Chronobiol. Int. 1993; 10: 395–400
   PubMed Web of Science ®Google Scholar
• Dunham N. W., Miya T. S. A note on simple apparatus for detecting neurological deficit in rats and mice. J. Am. Pharm. Assoc. 1957; 46: 208–209
   Google Scholar
• Focan C. Chronobiologic concepts underlying the chronotherapy of human lung cancer. Chronobiol. Int. 2002; 19: 253–273
   PubMed Web of Science ®Google Scholar
• Gooding S., Cunningham R. 5‐HT3‐receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side‐effect profile. Oncologist 2002; 7: 424–436
   PubMedGoogle Scholar
• Giacchette S. Chronotherapy of colorectal cancer. Chronobiol. Int. 2002; 19: 207–219
   PubMedGoogle Scholar
• Granda T. G., Lévi F. Tumor‐based rhythms of anticancer efficacy in experimental models. Chronobiol. Int. 2002; 19: 21–41
   PubMed Web of Science ®Google Scholar
• Haus E. Chronobiology of the mammalian response to ionizing radiation. Potential applications in oncology. Chronobiol. Int. 2002; 19: 77–100
   PubMed Web of Science ®Google Scholar
• Hendrie C. A. The 5‐HT3 antagonist GR38032F is highly toxic in DBA/2 mice. Psychopharmacology (Berl) 1990; 101: 429–430
   PubMedGoogle Scholar
• Hrushesky W. J. M., Roemeling V. R., Sothern B. R. Circadian chronotherapy: from animal experiments to human cancer chemotherapy. Chronopharmacology: Cellular and Biochemical Aspects of Interactions, B. Lemmer. Marcel Dekker, New YorkU.S.A. 1989; 439–473
   Google Scholar
• Ixart G., Szafarczyk A., Malaval F., Assenmacher I. Impairment of the ether stress induced ACTH surge in rats by ablation of the suprachiasmatic nuclei or by i.p. Injection of para‐chlorophenylalanine. Neuroendocrinol. Lett. 1985; 7: 171–174
   Web of Science ®Google Scholar
• Kobayashi M., To H., Tokue A., Fujimura A., Kobayashi E. Cisplatin‐induced vomiting depends on circadian timing. Chronobiol. Int. 2001; 18: 851–863
   PubMed Web of Science ®Google Scholar
• Kobayashi M., Wood P. A., Hrushesky W. J. M. Circadian chronotherapy for gynecological and genitourinary cancers. Chronobiol. Int. 2002; 19: 237–251
   PubMed Web of Science ®Google Scholar
• Lemmer B. Chronopharmacology: Cellular and Biochemical Aspects of Interactions, B. Lemmer. Marcel Dekker, New YorkU.S.A. 1989
   Google Scholar
• Lévi F. Chronopharmacologie et chronothérapie des cancers. Path. Biol. (Paris) 1996; 44: 631–644
   PubMedGoogle Scholar
• Lévi F. From circadian rhythms to cancer chronotherapeutics. Chronobiol. Int. 2002; 19: 1–19
   PubMed Web of Science ®Google Scholar
• Lindley C., Blower P. Oral serotonin type 3‐receptor antagonists for prevention of chemotherapy‐induced emesis. Am. J. Health Syst. Pharm. 2000; 57: 1685–1697
   PubMed Web of Science ®Google Scholar
• Marty M., Pouillart P., Scholl S., Droz J. P., Azab M., Brion N., Pujade‐Lauraine E., Paule B., Paes D., Bons J. Comparison of the 5‐hydroxytryptamine 3 (serotonin) antagonist ondansetron (GR 38032) with high‐dose metoclopramide in the control of cisplatin‐induced emesis. N. Engl. J. Med. 1990; 332: 816–821
   Google Scholar
• Miller L. C., Tainter M. L. Estimation of the ED50 and its error by means of logarithmic‐probit graph paper. Proc. Soc. Exp. Biol. Med. 1944; 57: 261–264
   Google Scholar
• Miner R. W.D., Sanger G. J. Inhibition of cisplatin‐induced vomiting by selective 5‐hydroxytryptamine M‐receptor antagonism. Br. J. Pharmacol. 1986; 88: 497–499
   PubMed Web of Science ®Google Scholar
• Moore Y. R., Silver R. Suprachiasmatic nucleus organization. Chronobiol. Int. 1998; 15: 475–487
   PubMed Web of Science ®Google Scholar
• Moore‐Ede M. C., Sulzman F. M., Fuller C. A. The Clock that Times Us. Harvard University Press, Cambridge, MA 1992; 448
   Google Scholar
• Mormont M. C., Boughattas N. A., Lévi F. Mechanisms of circadian rhythms in toxicity and efficacy of anticancer drugs: relevance for the development of new analogs. Chronopharmacology: Cellular and Biochemical Aspects of Interactions, B. Lemmer. Marcel Dekker, New YorkU.S.A. 1989; 395–435
   Google Scholar
• Nelson W., Tong Y., Lee J. K., Halberg F. Methods for cosinor rhythmometry. Chronobiologia 1979; 6: 305–323
   PubMedGoogle Scholar
• Rich T. A., Shelton C. H., III, Kirichenko A., Straume M. Chronomodulated chemotherapy and irradiation: an idea whose time has come. Chronobiol. Int. 2002; 19: 191–205
   PubMed Web of Science ®Google Scholar
• Rietveld W. J. The suprachiasmatic nucleus and other pacemarkers. Biological Rhythms in Clinical and Laboratory Medicine, Y. Touitou, E. Haus. Springer‐Verlag, Berlin 1992; 55–64
   Google Scholar
• Reinberg A. Concepts in chronopharmacology. Annu. Rev. Pharmacol. Toxicol. 1992; 32: 51–66
   PubMed Web of Science ®Google Scholar
• Reinberg A., Smolensky M. Investigate methodology for chronobiology. Biological Rhythms and Medicine. Cellular, Metabolic, Physiopathologic and Pharmacologic Aspects, A. Reinberg, M. Smolensky. Springer‐Verlag, New York 1983; 20–46
   Google Scholar
• Reinberg A., Le Fur I., Tschachler E. Problems related to circadian rhythms in human skin and their validation. J. Invest. Dermatol. 1998; 111: 708–709
   PubMed Web of Science ®Google Scholar
• Scheving L. E., Tsai T. H., Feuers R. J., Scheving L. A. Cellular mechanisms involved in the action of anticancer drugs. Chronopharmacology: Cellular and Biochemical Aspects of Interactions, B. Lemmer. Marcel Dekker, New YorkU.S.A. 1989; 317–369
   Google Scholar
• Simpson K. H., Hicks F. M. Clinical pharmacokinetics of ondansetron. A review. J. Pharm. Pharmacol. Ther. 1996; 48: 774–781
   PubMed Web of Science ®Google Scholar
• Stables R., Andrews P. L., Bailey H. E., Costall B., Gunning S. J., Hawthorn J., Naylor R. J., Tyers M. B. Anti‐emetic properties of the 5‐HT3 antagonist, GR38032F. Cancer Treat. Rev. 1987; 14: 333–336
   PubMed Web of Science ®Google Scholar